Imagine a WorldWhere metabolic balance is the norm,And patients live without compromise." We are developing and delivering novel therapies for rare diseases to significantly improve the quality of life for patients and their families. learn more Our lead development program: two Phase 3 programs in congenital and tumor hyperinsulinism. View Our Pipeline Check out stories about how patients and their families address the day-to-day challenges of living with hyperinsulinism. View patient Voices Recent Press Releases view all Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update 11/05/26 Rezolute to Participate in Upcoming Investor Conferences 11/02/26 Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism 10/14/26
